JP2013510885A5 - - Google Patents

Download PDF

Info

Publication number
JP2013510885A5
JP2013510885A5 JP2012539065A JP2012539065A JP2013510885A5 JP 2013510885 A5 JP2013510885 A5 JP 2013510885A5 JP 2012539065 A JP2012539065 A JP 2012539065A JP 2012539065 A JP2012539065 A JP 2012539065A JP 2013510885 A5 JP2013510885 A5 JP 2013510885A5
Authority
JP
Japan
Prior art keywords
formula
composition
compound
nhch
optical isomer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2012539065A
Other languages
English (en)
Japanese (ja)
Other versions
JP5650233B2 (ja
JP2013510885A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2010/056760 external-priority patent/WO2011060392A1/en
Publication of JP2013510885A publication Critical patent/JP2013510885A/ja
Publication of JP2013510885A5 publication Critical patent/JP2013510885A5/ja
Application granted granted Critical
Publication of JP5650233B2 publication Critical patent/JP5650233B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2012539065A 2009-11-13 2010-11-15 選択的スフィンゴシン−１−リン酸受容体変調因子および不斉合成方法 Active JP5650233B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US26130109P 2009-11-13 2009-11-13
US61/261,301 2009-11-13
US26247409P 2009-11-18 2009-11-18
US61/262,474 2009-11-18
PCT/US2010/056760 WO2011060392A1 (en) 2009-11-13 2010-11-15 Selective sphingosine 1 phosphate receptor modulators and methods of chiral synthesis

Related Child Applications (2)

Application Number Title Priority Date Filing Date
JP2013235966A Division JP5982705B2 (ja) 2009-11-13 2013-11-14 選択的スフィンゴシン−１−リン酸受容体変調因子および不斉合成方法
JP2014229895A Division JP2015038145A (ja) 2009-11-13 2014-11-12 選択的スフィンゴシン−１−リン酸受容体変調因子および不斉合成方法

Publications (3)

Publication Number Publication Date
JP2013510885A JP2013510885A (ja) 2013-03-28
JP2013510885A5 true JP2013510885A5 (enExample) 2014-01-09
JP5650233B2 JP5650233B2 (ja) 2015-01-07

Family

ID=43992106

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2012539065A Active JP5650233B2 (ja) 2009-11-13 2010-11-15 選択的スフィンゴシン−１−リン酸受容体変調因子および不斉合成方法
JP2013235966A Active JP5982705B2 (ja) 2009-11-13 2013-11-14 選択的スフィンゴシン−１−リン酸受容体変調因子および不斉合成方法
JP2014229895A Pending JP2015038145A (ja) 2009-11-13 2014-11-12 選択的スフィンゴシン−１−リン酸受容体変調因子および不斉合成方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2013235966A Active JP5982705B2 (ja) 2009-11-13 2013-11-14 選択的スフィンゴシン−１−リン酸受容体変調因子および不斉合成方法
JP2014229895A Pending JP2015038145A (ja) 2009-11-13 2014-11-12 選択的スフィンゴシン−１−リン酸受容体変調因子および不斉合成方法

Country Status (32)

Country Link
US (4) US8362048B2 (enExample)
EP (3) EP3868377A1 (enExample)
JP (3) JP5650233B2 (enExample)
KR (2) KR101752124B1 (enExample)
CN (2) CN105061350B (enExample)
AU (1) AU2010319983B2 (enExample)
BR (2) BR112012011427B8 (enExample)
CA (2) CA2780772C (enExample)
CY (3) CY1120338T1 (enExample)
DK (2) DK2498610T4 (enExample)
EA (2) EA024801B1 (enExample)
ES (2) ES2858337T3 (enExample)
FI (1) FI2498610T4 (enExample)
FR (1) FR20C1059I2 (enExample)
HR (2) HRP20180874T4 (enExample)
HU (3) HUE054000T2 (enExample)
IL (2) IL219691B (enExample)
LT (3) LT2498610T (enExample)
LU (1) LUC00184I2 (enExample)
MX (1) MX2012005560A (enExample)
MY (2) MY189750A (enExample)
NO (2) NO2498610T3 (enExample)
NZ (1) NZ599915A (enExample)
PH (2) PH12012500939A1 (enExample)
PL (2) PL2498610T5 (enExample)
PT (2) PT3406142T (enExample)
RS (2) RS57253B2 (enExample)
SG (1) SG10201407357PA (enExample)
SI (2) SI3406142T1 (enExample)
SM (2) SMT201800288T1 (enExample)
TR (1) TR201807912T4 (enExample)
WO (1) WO2011060392A1 (enExample)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2665461T3 (es) * 2009-11-13 2018-04-25 Celgene International Ii Sàrl Moduladores del receptor esfingosina 1-fosfato y métodos de síntesis quiral
JP5650233B2 (ja) 2009-11-13 2015-01-07 レセプトス インコーポレイテッドＲｅｃｅｐｔｏｓ， Ｉｎｃ． 選択的スフィンゴシン−１−リン酸受容体変調因子および不斉合成方法
WO2012158550A2 (en) 2011-05-13 2012-11-22 Receptos, Inc. Selective heterocyclic sphingosine 1 phosphate receptor modulators
KR101951519B1 (ko) * 2012-06-21 2019-02-22 에자이 알앤드디 매니지먼트 가부시키가이샤 신규한 인단설파미드 유도체
WO2014158302A1 (en) * 2013-03-25 2014-10-02 Swenson Rolf Eric Novel sphingosine 1-phosphate receptor antagonists
WO2015066515A1 (en) * 2013-11-01 2015-05-07 Receptos, Inc. Selective sphingosine 1 phosphate receptor modulators and combination therapy therewith
AU2016246398A1 (en) 2015-04-06 2017-10-26 Auspex Pharmaceuticals, Inc. Deuterium-substituted oxadiazoles
WO2017215617A1 (zh) 2016-06-14 2017-12-21 苏州科睿思制药有限公司 奥扎莫德的晶型、其盐酸盐的晶型及其制备方法
US11192886B2 (en) 2016-07-22 2021-12-07 Medshine Discovery Inc. S1P1 agonist and application thereof
EP3502100A1 (en) * 2016-08-19 2019-06-26 Crystal Pharmaceutical (Suzhou) Co., Ltd. Crystal forms of ozanimod and preparation method therefor
US10882830B2 (en) 2016-09-14 2021-01-05 Receptos Llc Crystal form of ozanimod hydrochloride and processes for preparation therefor
US11117875B2 (en) 2016-09-14 2021-09-14 Hangzhou Solipharma Co., Ltd. Crystalline forms, preparation methods and pharmaceutical compositions of ozanimod
WO2018064356A1 (en) 2016-09-29 2018-04-05 Celgene International Ii Sarl Compounds and methods for treating lupus
JP7123956B2 (ja) * 2017-02-28 2022-08-23 ヘリオイースト・ファーマシューティカル・カンパニー・リミテッド スピロ化合物およびその使用
WO2018184185A1 (zh) * 2017-04-07 2018-10-11 杭州领业医药科技有限公司 奥扎莫德加成盐晶型、制备方法及药物组合物和用途
CN108727291A (zh) * 2017-04-21 2018-11-02 宁波爱诺医药科技有限公司 奥扎莫德及其中间体的制备方法
CN108727292A (zh) * 2017-04-21 2018-11-02 宁波爱诺医药科技有限公司 一种奥扎莫德及其中间体的制备方法
WO2018208855A1 (en) 2017-05-08 2018-11-15 Celgene International Ii Sarl Sphingosine 1 phosphate receptor agonists for neuroprotection
ES2960051T3 (es) * 2017-05-22 2024-02-29 Egyt Gyogyszervegyeszeti Gyar Proceso para la producción de ozanimod
US10660879B2 (en) 2017-06-23 2020-05-26 Enzo Biochem, Inc. Sphingosine pathway modulating compounds for the treatment of cancers
EP3641743A2 (en) 2017-06-23 2020-04-29 Enzo Biochem, Inc. Sphingosine pathway modulating compounds for the treatment of cancers
CN109280035B (zh) * 2017-07-19 2023-06-09 广东东阳光药业有限公司 奥扎莫德的多晶型及其制备方法
WO2019042219A1 (zh) 2017-08-31 2019-03-07 苏州科睿思制药有限公司 奥扎莫德盐酸盐的晶型及其制备方法
WO2019058290A1 (en) * 2017-09-20 2019-03-28 Suven Life Sciences Limited IMPROVED PROCESS FOR THE PREPARATION OF AZANIMOD A-AMINO COMPOUND
WO2019094409A1 (en) 2017-11-07 2019-05-16 Teva Pharmaceuticals International Gmbh Salts and solid state forms of ozanimod
CN107857760A (zh) * 2017-11-21 2018-03-30 南京天翔医药科技有限公司 鞘氨醇‑1‑磷酸受体调节剂及其应用
US11465995B2 (en) 2018-01-18 2022-10-11 Medshine Discovery Inc. Crystal and salt forms of tricyclic compound and preparation process thereof
AU2019239394A1 (en) 2018-03-20 2020-08-13 Eisai R&D Management Co., Ltd. Epilepsy treatment agent
CN110615747A (zh) * 2018-06-20 2019-12-27 广东东阳光药业有限公司 一种二氢茚中间体的制备方法
WO2020005313A1 (en) 2018-06-25 2020-01-02 Enzo Biochem, Inc. Sphingosine pathway modulating compounds for the treatment of cancers
EP3849965A1 (en) 2018-09-12 2021-07-21 Pharmazell GmbH A process for the preparation of ozanimod and its intermediate (s)-1-amino-2,3-dihydro-1h-indene-4-carbonitrile
AR116479A1 (es) 2018-09-25 2021-05-12 Quim Sintetica S A Intermediarios para la síntesis de ozanimod y procedimiento para la preparación del mencionado agonista del receptor de esfingosina-1-fosfato y de dichos intermediarios
ES2962211T3 (es) 2018-12-07 2024-03-18 Synthon Bv Proceso mejorado para preparar ozanimod
US20220144788A1 (en) * 2019-03-29 2022-05-12 Receptos Llc Sphingosine 1 phosphate receptor modulators
WO2020205483A1 (en) * 2019-03-29 2020-10-08 Celgene International Ii Sarl Sphingosine 1 phosphate receptor modulators
WO2020205481A1 (en) * 2019-03-29 2020-10-08 Celgene International Ii Sarl Sphingosine 1 phosphate receptor modulators
WO2020219207A1 (en) * 2019-04-26 2020-10-29 Celgene International Ii Sarl Sphingosine 1 phosphate receptor modulator
CN112062785B (zh) * 2019-06-11 2023-06-27 广东东阳光药业有限公司 奥扎莫德及其中间体的制备方法
MX2022000651A (es) 2019-07-16 2022-03-11 Synthon Bv Proceso mejorado para preparar ozanimod.
PH12022551043A1 (en) 2019-10-31 2023-05-03 Idorsia Pharmaceuticals Ltd Combination of a cxcr7 antagonist with an s1p1 receptor modulator
WO2021142030A1 (en) * 2020-01-06 2021-07-15 Arena Pharmaceuticals, Inc. Methods of treating conditions related to the s1p1 receptor
EP4545078A3 (en) 2020-03-04 2025-07-30 Helioeast Pharmaceutical Co., Ltd. Benzo 2-azaspiro[4.4]nonane compound and use thereof
EP4116295A4 (en) * 2020-03-04 2023-08-02 Helioeast Pharmaceutical Co., Ltd. TRICYCLIC COMPOUNDS AND THEIR USE
EP4121025A4 (en) 2020-03-17 2024-03-27 Enzo Biochem, Inc. Sphingosine pathway modulating compounds for the treatment of coronavirus infection
JP2023518968A (ja) * 2020-03-27 2023-05-09 レセプトス・リミテッド・ライアビリティ・カンパニー スフィンゴシン１ホスフェート受容体モジュレーター
JP7653447B2 (ja) * 2020-03-27 2025-03-28 レセプトス・リミテッド・ライアビリティ・カンパニー スフィンゴシン１ホスフェート受容体モジュレーター
EP4126826A1 (en) 2020-04-02 2023-02-08 Synthon B.V. Crystalline form of ozanimod hydrochloride
CN111620788B (zh) * 2020-04-20 2022-09-30 广东莱佛士制药技术有限公司 一种制备(2s,3s)-3-氨基-二环[2.2.2]辛烷-2-甲酸酯的方法
WO2022213935A1 (zh) * 2021-04-09 2022-10-13 南昌弘益药业有限公司 噁二唑取代的螺环类化合物及其应用
EP4212156A1 (en) 2022-01-13 2023-07-19 Abivax Combination of 8-chloro-n-(4-(trifluoromethoxy)phenyl)quinolin-2-amine and its derivatives with a s1p receptor modulator
WO2023152767A1 (en) 2022-02-11 2023-08-17 Mylan Laboratories Limited Polymorphic forms of ozanimod hydrochloride
WO2024246174A1 (en) 2023-05-31 2024-12-05 Química Sintética, S.A. Amorphous and crystalline form of ozanimod hydrochloride
TW202535949A (zh) 2023-12-20 2025-09-16 美商必治妥美雅史谷比公司 靶向IL-18受體β(IL-18RB)之抗體及相關方法
CN119462405B (zh) * 2025-01-10 2025-05-27 天津阿尔塔科技有限公司 一种氘标记鞘氨醇类化合物和氘标记神经酰胺类化合物的制备方法和应用

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1479544A (en) 1974-02-07 1977-07-13 American Cyanamid Co 1,2,3,4-tetrahydro-1-naphthylurea derivatives their preparation and their use
FR2628103B1 (fr) * 1988-03-03 1991-06-14 Roussel Uclaf Nouveaux esters pyrethrinoides portant un noyau indanyle, leur procede de preparation et leur application comme pesticides
US5039802A (en) 1990-04-18 1991-08-13 Merck & Co., Inc. Arylation process for preparation of chiral catalysts for ketone reduction
JPH0825973B2 (ja) 1991-04-12 1996-03-13 シェリング・コーポレーション アシル補酵素ａ：コレステロールアシルトランスフェラーゼの阻害剤としての二環式アミド
GB2290790A (en) 1994-06-30 1996-01-10 Merck & Co Inc Asymmetric synthesis of 6-substituted 2-amino-1,2,3,4-tetrahydronaphthalenes
ID25477A (id) * 1998-01-23 2000-10-05 Sankyo Co Turunan-turunan spiropiperidin
AR035585A1 (es) † 2000-09-15 2004-06-16 Pharmacia Corp Derivados del acido 2-amino-2-alquil-4-heptenoico, composicion farmaceutica y su uso en la fabricacion de medicamentos
US20040058894A1 (en) 2002-01-18 2004-03-25 Doherty George A. Selective S1P1/Edg1 receptor agonists
DE60335827D1 (de) * 2002-12-20 2011-03-03 Merck Sharp & Dohme 1-(amino)indane als edg-rezeptoragonisten
PT3345895T (pt) 2003-04-11 2020-01-29 Ptc Therapeutics Inc Composto de ácido 1,2,4-oxadiazole benzóico e a sua utilização para a supressão sem sentido e tratamento de doenças
CN1859908A (zh) * 2003-10-01 2006-11-08 默克公司 作为s1p受体激动剂的3,5－芳基、杂芳基或环烷基取代的－1,2,4－噁二唑类化合物
WO2005058848A1 (en) * 2003-12-17 2005-06-30 Merck & Co., Inc. (3,4-disubstituted)propanoic carboxylates as s1p (edg) receptor agonists
US7585881B2 (en) * 2004-02-18 2009-09-08 Astrazeneca Ab Additional heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists
US20060173183A1 (en) 2004-12-31 2006-08-03 Alantos Pharmaceuticals, Inc., Multicyclic bis-amide MMP inhibitors
EP1851188A1 (en) 2005-02-22 2007-11-07 Teva Pharmaceutical Industries Limited Improved process for the synthesis of enantiomeric indanylamine derivatives
KR100667075B1 (ko) 2005-07-22 2007-01-10 삼성에스디아이 주식회사 주사 구동부 및 이를 포함하는 유기 전계발광 표시장치
HUE028025T2 (en) † 2005-08-03 2016-11-28 Novartis Ag Use of Panobinostat HDAC inhibitor to treat myeloma
US7582803B2 (en) 2005-09-14 2009-09-01 Amgen Inc. Conformationally constrained 3-(4-hydroxy-phenyl)-substituted-propanoic acids useful for treating metabolic disorders
PE20070705A1 (es) * 2005-11-25 2007-08-23 Basf Ag Compuestos de indanil - y tetrahidronaftil-amino-azolina para combatir pestes animales
EP1963509A4 (en) 2005-12-21 2009-07-29 Joseph Gabriele CATECHOLAMINE-REGULATED PROTEIN
CA2643055A1 (en) 2006-03-13 2007-09-20 Pfizer Products Inc. Tetralines antagonists of the h-3 receptor
US20080009534A1 (en) * 2006-07-07 2008-01-10 Bristol-Myers Squibb Company Substituted acid derivatives useful as antidiabetic and antiobesity agents and method
JP5250556B2 (ja) * 2006-09-21 2013-07-31 アクテリオン ファーマシューティカルズ リミテッド フェニル誘導体及びそれらの免疫調節薬としての使用
EP2099741A2 (en) 2006-11-21 2009-09-16 University Of Virginia Patent Foundation Hydrindane analogs having sphingosine 1-phosphate receptor agonist activity
NZ577111A (en) * 2006-12-15 2012-05-25 Abbott Lab Novel oxadiazole compounds
JO2701B1 (en) 2006-12-21 2013-03-03 جلاكسو جروب ليميتد Vehicles
WO2008106226A2 (en) 2007-02-28 2008-09-04 Rib-X Pharmaceuticals, Inc. Macrolide compounds and methods of making and using the same
GB0725104D0 (en) † 2007-12-21 2008-01-30 Glaxo Group Ltd Compounds
WO2009131090A1 (ja) 2008-04-21 2009-10-29 旭化成ファーマ株式会社 アミノ酸化合物
EA021672B1 (ru) 2008-05-14 2015-08-31 Дзе Скриппс Рисёч Инститьют Модуляторы рецепторов сфингозин-1-фосфата и их применение
US8485794B2 (en) * 2008-06-13 2013-07-16 Doowon Technical College Reciprocating compressor with rotary valve
GB0910674D0 (en) 2009-06-19 2009-08-05 Glaxo Group Ltd Novel compounds
WO2011005290A1 (en) 2009-06-23 2011-01-13 Arena Pharmaceuticals, Inc. Disubstituted oxadiazole derivatives useful in the treatment of autoimmune and inflammatory disorders
GB0911130D0 (en) 2009-06-26 2009-08-12 Glaxo Group Ltd Novel compounds
ES2665461T3 (es) * 2009-11-13 2018-04-25 Celgene International Ii Sàrl Moduladores del receptor esfingosina 1-fosfato y métodos de síntesis quiral
JP5650233B2 (ja) 2009-11-13 2015-01-07 レセプトス インコーポレイテッドＲｅｃｅｐｔｏｓ， Ｉｎｃ． 選択的スフィンゴシン−１−リン酸受容体変調因子および不斉合成方法
CA2780641C (en) 2009-11-13 2019-03-05 Receptos, Inc. Selective heterocyclic sphingosine 1 phosphate receptor modulators
WO2012158550A2 (en) 2011-05-13 2012-11-22 Receptos, Inc. Selective heterocyclic sphingosine 1 phosphate receptor modulators
WO2013055907A1 (en) 2011-10-12 2013-04-18 Teva Pharmaceutical Industries Ltd. Treatment of multiple sclerosis with combination of laquinimod and fingolimod

Similar Documents

Publication Publication Date Title
JP2013510885A5 (enExample)
JP2015505296A5 (enExample)
JP2014506907A5 (enExample)
JP2016534063A5 (enExample)
JP2011527691A5 (enExample)
JP2013032389A5 (enExample)
JP2013537203A5 (enExample)
JP2012092103A5 (enExample)
SI2498610T1 (en) SELECTIVE MODERATORS OF SFINGOSIN-1-PHOSPHATE RECEPTOR AND CIRAL SYNTHESIS PROCEDURES
JP2009242409A5 (enExample)
JP2012532883A5 (enExample)
JP2009535358A5 (enExample)
AR047972A1 (es) Derivado de bencimidazol, proceso de obtencion y composiciones farmaceuticas.
JP2020507589A5 (enExample)
JP2009504748A5 (enExample)
JP2018537535A5 (enExample)
JP2010536766A5 (enExample)
JP2007302689A5 (enExample)
JP2013542992A5 (enExample)
JP2015535847A5 (enExample)
JP2010529994A5 (enExample)
JP2009543795A5 (enExample)
JP2013533253A5 (enExample)
JP2019516739A5 (enExample)
JP2015509075A5 (enExample)